Drugs & Targets FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma March 27, 2026Vol.52 No.12
Drugs & Targets FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer March 27, 2026Vol.52 No.12
Drugs & Targets FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC March 27, 2026Vol.52 No.12
Cancer Policy FDA launches consolidated adverse event reporting system March 20, 2026Vol.52 No.11By Claire Marie Porter
Regulatory News Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again) March 13, 2026Vol.52 No.10By Claire Marie Porter
Regulatory News Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncologyAtara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.” March 13, 2026Vol.52 No.10By Jacquelyn Cobb
Cancer Policy FDA approves leucovorin for cerebral folate deficiency March 13, 2026Vol.52 No.10By Claire Marie Porter
Drugs & Targets FDA approves teclistamab + daratumumab hyaluronidase-fihj for r/r MM March 06, 2026Vol.52 No.09
Drugs & Targets FDA grants tentative approval for Lutetium Lu 177 dotatate March 06, 2026Vol.52 No.09
